331 related articles for article (PubMed ID: 23374145)
21. Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.
Offidani M; Corvatta L; Caraffa P; Leoni P; Pautasso C; Larocca A; Palumbo A
Expert Rev Anticancer Ther; 2014 May; 14(5):499-510. PubMed ID: 24738833
[TBL] [Abstract][Full Text] [Related]
22. Acquisition of MHC:peptide complexes by dendritic cells contributes to the generation of antiviral CD8+ T cell immunity in vivo.
Smyth LA; Hervouet C; Hayday T; Becker PD; Ellis R; Lechler RI; Lombardi G; Klavinskis LS
J Immunol; 2012 Sep; 189(5):2274-82. PubMed ID: 22821960
[TBL] [Abstract][Full Text] [Related]
23. Suppression of murine tumour growth through CD8
Kogo H; Shimizu M; Negishi Y; Uchida E; Takahashi H
Immunology; 2017 Jul; 151(3):324-339. PubMed ID: 28294313
[TBL] [Abstract][Full Text] [Related]
24. Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn
Röhner L; Ng YLD; Scheffold A; Lindner S; Köpff S; Brandl A; Beilhack A; Krönke J
Exp Hematol; 2021 Jan; 93():61-69.e4. PubMed ID: 33186626
[TBL] [Abstract][Full Text] [Related]
25. Langerin+ CD8alpha+ dendritic cells are critical for cross-priming and IL-12 production in response to systemic antigens.
Farrand KJ; Dickgreber N; Stoitzner P; Ronchese F; Petersen TR; Hermans IF
J Immunol; 2009 Dec; 183(12):7732-42. PubMed ID: 19923446
[TBL] [Abstract][Full Text] [Related]
26. IL-10 promotes homeostatic proliferation of human CD8(+) memory T cells and, when produced by CD1c(+) DCs, shapes naive CD8(+) T-cell priming.
Nizzoli G; Larghi P; Paroni M; Crosti MC; Moro M; Neddermann P; Caprioli F; Pagani M; De Francesco R; Abrignani S; Geginat J
Eur J Immunol; 2016 Jul; 46(7):1622-32. PubMed ID: 27129615
[TBL] [Abstract][Full Text] [Related]
27. β-catenin mediates tumor-induced immunosuppression by inhibiting cross-priming of CD8⁺ T cells.
Liang X; Fu C; Cui W; Ober-Blöbaum JL; Zahner SP; Shrikant PA; Clausen BE; Flavell RA; Mellman I; Jiang A
J Leukoc Biol; 2014 Jan; 95(1):179-90. PubMed ID: 24023259
[TBL] [Abstract][Full Text] [Related]
28. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.
Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL
Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491
[TBL] [Abstract][Full Text] [Related]
29. LOX-1 as a natural IFN-alpha-mediated signal for apoptotic cell uptake and antigen presentation in dendritic cells.
Parlato S; Romagnoli G; Spadaro F; Canini I; Sirabella P; Borghi P; Ramoni C; Filesi I; Biocca S; Gabriele L; Belardelli F
Blood; 2010 Feb; 115(8):1554-63. PubMed ID: 20009034
[TBL] [Abstract][Full Text] [Related]
30. A Highly Active Form of XCL1/Lymphotactin Functions as an Effective Adjuvant to Recruit Cross-Presenting Dendritic Cells for Induction of Effector and Memory CD8
Matsuo K; Kitahata K; Kawabata F; Kamei M; Hara Y; Takamura S; Oiso N; Kawada A; Yoshie O; Nakayama T
Front Immunol; 2018; 9():2775. PubMed ID: 30542351
[TBL] [Abstract][Full Text] [Related]
31. Baccatin III, a synthetic precursor of taxol, enhances MHC-restricted antigen presentation in dendritic cells.
Lee YH; Lee YR; Kim KH; Im SA; Song S; Lee MK; Kim Y; Hong JT; Kim K; Lee CK
Int Immunopharmacol; 2011 Aug; 11(8):985-91. PubMed ID: 21354357
[TBL] [Abstract][Full Text] [Related]
32. Activated NKT Cells Can Condition Different Splenic Dendritic Cell Subsets To Respond More Effectively to TLR Engagement and Enhance Cross-Priming.
Osmond TL; Farrand KJ; Painter GF; Ruedl C; Petersen TR; Hermans IF
J Immunol; 2015 Aug; 195(3):821-31. PubMed ID: 26078270
[TBL] [Abstract][Full Text] [Related]
33. Sustained cross-presentation capacity of murine splenic dendritic cell subsets in vivo.
Ho NI; Camps MGM; de Haas EFE; Ossendorp F
Eur J Immunol; 2018 Jul; 48(7):1164-1173. PubMed ID: 29676785
[TBL] [Abstract][Full Text] [Related]
34. ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells.
Duewell P; Kisser U; Heckelsmiller K; Hoves S; Stoitzner P; Koernig S; Morelli AB; Clausen BE; Dauer M; Eigler A; Anz D; Bourquin C; Maraskovsky E; Endres S; Schnurr M
J Immunol; 2011 Jul; 187(1):55-63. PubMed ID: 21613613
[TBL] [Abstract][Full Text] [Related]
35. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
[TBL] [Abstract][Full Text] [Related]
36. Loss of Phagocytic and Antigen Cross-Presenting Capacity in Aging Dendritic Cells Is Associated with Mitochondrial Dysfunction.
Chougnet CA; Thacker RI; Shehata HM; Hennies CM; Lehn MA; Lages CS; Janssen EM
J Immunol; 2015 Sep; 195(6):2624-32. PubMed ID: 26246142
[TBL] [Abstract][Full Text] [Related]
37. Monoclonal antibodies targeted against melanoma and ovarian tumors enhance dendritic cell-mediated cross-presentation of tumor-associated antigens and efficiently cross-prime CD8+ T cells.
Cioca DP; Deak E; Cioca F; Paunescu V
J Immunother; 2006; 29(1):41-52. PubMed ID: 16365599
[TBL] [Abstract][Full Text] [Related]
38. Polyethyleneimine modification of aluminum hydroxide nanoparticle enhances antigen transportation and cross-presentation of dendritic cells.
Dong H; Wen ZF; Chen L; Zhou N; Liu H; Dong S; Hu HM; Mou Y
Int J Nanomedicine; 2018; 13():3353-3365. PubMed ID: 29922056
[TBL] [Abstract][Full Text] [Related]
39. Increased antigen cross-presentation but impaired cross-priming after activation of peroxisome proliferator-activated receptor gamma is mediated by up-regulation of B7H1.
Klotz L; Hucke S; Thimm D; Classen S; Gaarz A; Schultze J; Edenhofer F; Kurts C; Klockgether T; Limmer A; Knolle P; Burgdorf S
J Immunol; 2009 Jul; 183(1):129-36. PubMed ID: 19535643
[TBL] [Abstract][Full Text] [Related]
40. Combination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer model.
Vo MC; Nguyen-Pham TN; Lee HJ; Jaya Lakshmi T; Yang S; Jung SH; Kim HJ; Lee JJ
Oncotarget; 2017 Apr; 8(16):27252-27262. PubMed ID: 28460478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
